2-amino-3-hydroxy-5-phenyl-valeric acid | 147331-56-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-3-hydroxy-5-phenyl-valeric acid
• 英文别名: 2-Amino-3-hydroxy-5-phenyl-valeriansaeure；2-amino-3-hydroxy-5-phenylpentanoic acid；(2S,3S)-2-Amino-3-hydroxy-5-phenylpentanoic acid
• CAS: 147331-56-4
• 化学式: C₁₁H₁₅NO₃
• 分子量: 209.245
• InChiKey: YZSJSPHAYXNTPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-amino-3-hydroxy-5-phenyl-valeric acid 生成 2-benzoylamino-3-hydroxy-5-phenyl-valeric acid
  参考文献：
  名称：

  The impact of gender, body dimension and body composition on hand-grip strength in healthy children

  摘要：

  Maximum hand-grip (HG) strength, body composition and main anthropometric variables were evaluated in 278 children with normal weight and growth, aged 5-15 yr divided into 3 age groups: group 1, age+/-SD: 7.6+/-0.9 yr 7.6+/-0.9 SD (Tanner stage 1); group 2, age: 10.8+/-0.7 yr (Tanner stage: 2-3); group 3, age: 1 3.2+/-0.9 yr (Tanner stage: 4-5). Weight, height, body surface area (BSA), BMI, percent body fat (BF) and fat free mass (FFM) increased progressively and significantly from the younger to the older age group. A significant difference between genders was detected only for BF and FFM, females having a higher fat mass and a lower FFM compared to males. Most children were right-handed (91%). In either genders, a curvilinear relation was detected between HG strength and age, with best fit for the dominant (d) hand given by the equations: dHG=5.891 *10(0.051 age), r(2)=0.986, p<0.001 in males and dHG=6.163 *10(0.045 age), r(2)=0.973, p<0.001 in females. The increase in HG strength after 11 yr appears to be steeper in males as compared with that found in females. In both d and non-dominant (nd) hand, a significant difference in HG strength was detected between males and females, the average difference being about 10% at all ages. For both genders, nd hand was significantly weaker than d hand in the older age groups (2 and 3), but not in the younger group 1. Age and gender-dependent differences in HG strength (but not differences between d and nd hand) disappear if HG strength is normalized for FFM. Thus, in general, dHG strength normalized for FFM resulted on average to be 0.67+/-0.11 kg/kg. A multiple linear regression analysis indicated that HG was positively correlated with BMI, BSA, stature, stature(2) and FFM (p<0.001 for all correlations) without differences between genders, while a negative correlation was found between HG strength and %BF. The most significant correlation was found between HG strength and FFM, without any significant difference between genders, so that the overall equation describing the line for the d hand was: dHG strength = 2.32+0.63 FFM, r(2)=0.72, p<0.001. In conclusion, the present study indicates that the age-dependent increase of HG strength as well as the between-gender differences are strongly related to changes of FFM values occurring during childhood. Moreover, the study provides a standard normative value of maximal HG strength for the healthy children population in Northern Italy.

  DOI：

  10.1007/bf03344033
• 作为产物：
  描述：

  2-amino-3-hydroxy-5-phenylpentanoic acid hydrochloride 在 sodium hydroxide 、 水 作用下， 以53%的产率得到2-amino-3-hydroxy-5-phenyl-valeric acid
  参考文献：
  名称：

  NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID

  摘要：

  公开号：

  EP2050738B1

文献信息

• COMPOUNDS AND METHODS OF TREATING METABOLIC SYNDROME AND INFLAMMATION
  申请人：Nestor John J.

  公开号：US20080139455A1

  公开（公告）日：2008-06-12

  Novel compounds, compositions comprising compounds, and methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis, restenosis, sepsis, type 1 diabetes, liver damage, and cachexia, by administering compounds described herein. Compounds presented herein may be used to modulate serine palmitoyltransferase activity.

  本文描述了新型化合物、包含化合物的组合物以及制备和使用化合物的方法。本文还描述了使用化合物治疗或改善各种疾病的方法，包括胰岛素抵抗、胰岛β细胞凋亡、肥胖症、促凝血状态、心肌梗死、高血压、血脂异常、X综合征表现、充血性心力衰竭、心血管系统炎症性疾病、动脉硬化、再狭窄、败血症、1型糖尿病、肝损伤和消瘦症。本文所述的化合物可用于调节丝氨酸棕榈酰转移酶活性。
• Enzyme inhibiting peptide derivatives
  申请人：BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC.

  公开号：EP0401675A1

  公开（公告）日：1990-12-12

  Disclosed herein are peptide derivatives which inhibit the activities of human immunodeficiency virus (HIV) protease and renin. The peptide derivatives can be represented by general formula R¹-R²-Y-R³-R⁴ wherein R¹ is a derived amino acid based on an O⁴-(carboxymethyl)-tyrosyl residue, R² and R³ are amino acid or analogous amino acid residues (R³ may optionally be absent), Y is a non-peptide linking unit, e.g. statyl, and R⁴ is [NR¹⁷CHR¹⁸-C(O)]p-Z wherein R¹⁷ is hydrogen or lower alkyl, R¹⁸ is an amino acid or analogous amino acid side chain, p is zero or one and Z is a terminal group (e.g. hydroxy or amino), or R⁴ is NR¹⁷CR¹⁸(R²¹)CH₂OH wherein R¹⁷ and R¹⁸ are as noted hereinabove and R²¹ is hydrogen, lower alkyl or hydroxy-­(lower)alkyl. The derivatives are useful as agents for combating HIV infections and for treating renin-associated hypertension and congestive heart failure.

  本文公开的肽衍生物可抑制人体免疫缺陷病毒（HIV）蛋白酶和肾素的活性。这些肽衍生物可由通式 R¹-R²-Y-R³-R⁴ 表示，其中 R¹ 是基于 O⁴-（羧甲基）-酪氨酰残基的衍生氨基酸，R² 和 R³ 是氨基酸或类似氨基酸残基（R³ 可以选择性地缺失），Y 是非肽连接单元，如[NR¹⁴-(羧甲基)-酪氨酰]，R² 和 R³ 是[NR¹⁴-(羧甲基)-酪氨酰]。其中 R¹⁷ 是氢或低级烷基，R¹⁸ 是氨基酸或类似氨基酸侧链，p 是 0 或 1，Z 是末端基团（如羟基或氨基）。例如羟基或氨基），或 R⁴ 是 NR¹⁷CR¹⁸(R²¹)CH₂OH，其中 R¹⁷ 和 R¹⁸ 如上所述，R²¹ 是氢、低级烷基或羟基-（低级）烷基。这些衍生物可作为抗 HIV 感染和治疗肾素相关性高血压和充血性心力衰竭的药物。
• US6274708B1
  申请人：——

  公开号：US6274708B1

  公开（公告）日：2001-08-14
• US7947722B2
  申请人：——

  公开号：US7947722B2

  公开（公告）日：2011-05-24
• [EN] THERAPEUTIC PEPTIDES<br/>[FR] PEPTIDES THÉRAPEUTIQUES
  申请人：COHBAR INC

  公开号：WO2021155194A1

  公开（公告）日：2021-08-05

  The disclosures herein relate to the fields of cell biology and the modulation of cellular mechanisms controlling cell viability, cell proliferation, and metabolic processes. More specifically disclosed herein are peptides effective to modulate cellular mechanisms controlling cell viability, cell proliferation, and metabolic processes, including cell signaling associated with aberrant cellular proliferation and malignancy. Also disclosed herein are peptides effective in modulating cellular mechanisms controlling cell viability, treating metabolic diseases, and as cytoprotective agents.